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CASE REPORT
Fig. 1. Histology shows subcorneal pustules with perivascular 
lymphoplasmacytic infiltrates admixed with neutrophils and 
occasional eosinophils (H&E, ×100).
Acute Generalized Exanthematous Pustulosis Caused by 
Daptomycin
Teoh Yee Leng, M.D., Mark Koh Jean Aan, M.D., Michelle Chan, M.D.
1, Liu Tsun Tsien, M.D.
Department of Dermatology, Changi General Hospital, Singapore 529889,
 1Department of Pathology, Singapore General Hospital, 
Singapore 169608, Singapore
Daptomycin, a lipopeptide antibiotic with similar action as 
vancomycin, is used to treat complicated skin and soft tissue 
infections caused by resistant Gram-positive bacteria, in-
cluding methicillin-resistant Staphylococcus aureus, peni-
cillin-resistant streptococci, and vancomycin-resistant enter-
ococci. Acute generalized exanthematous pustulosis (AG-
EP), characterized by acute onset of numerous sterile, non- 
follicular pinhead sized pustules, is common secondary to 
drugs, in particular, antibiotics. We present the first case of 
AGEP following the use of daptomycin. (Ann Dermatol 
23(S3) S288∼S289, 2011)
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INTRODUCTION
Acute generalized exanthematous pustulosis (AGEP), a 
self-limiting drug eruption, commonly occur secondary to 
antibiotics. We present a first case of AGEP after treatment 
with daptomycin, an antibiotic used to treat infections 
caused by methicillin-resistant Staphylococcus aureus, 
penicillin-resistant streptococci and vancomycin-resistant 
enterococci. 
CASE REPORT
A 57-year-old man, with underlying problems of hyper-
tension and poorly controlled diabetes mellitus, was 
admitted for right foot osteomyelitis with septic shock. He 
had no history of skin disease. He underwent a right 
below-knee amputation and was post-operatively started 
on vancomycin for methicillin-resistant Staphylococcus 
aureus (MRSA) bacteraemia. However, due to poor clini-
cal response and persistently high vancomycin minimum 
inhibitory concentration levels, vancomycin was switched 
to intravenous daptomycin.
On day 24 of daptomycin administration, the patient de-
veloped a non-pruritic generalised maculopapular ery-
thematous rash over the trunk and limbs, with no mucosal 
involvement. He had a temperature of 38.6
oC, leuco-
cytosis of 17.6×10
9/L, and an absolute neutrophil count Acute Generalized Exanthematous Pustulosis Caused by Daptomycin
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of 8.4×10
3/μl. Skin scraping for fungal microscopy was 
negative. Six days later, the rash became more extensive 
with small pit-point pustules and superficial scaling. A skin 
biopsy (Fig. 1) showed subcorneal pustules with a peri-
vascular infiltrate consisting mainly of lymphocytes and 
plasma cells with some neutrophils and scattered eosi-
nophils. No fungal hyphae or spores were seen.
A diagnosis of acute generalized exanthematous pustul-
osis (AGEP) due to daptomycin was made after excluding 
other possible causative drugs. However, in view of the 
MRSA bacteraemia and recurrent osteomyelitis, a decision 
was made to complete 6 weeks of daptomycin therapy. 
He was treated symptomatically with topical corticos-
teroids, moisturisers, and antihistamines. Two weeks after 
completing the daptomycin course, the rash improved, 
with residual scattered superficial scaly patches and post- 
inflammatory hyperpigmentation. 
DISCUSSION
AGEP is an eruption triggered most often by drugs, and 
antibiotics (penicillins, quinolones, and macrolides) are 
the most frequent cause. Daptomycin, a lipopeptide an-
tibiotic with similar action as vancomycin, is used to treat 
complicated skin and soft tissue infections caused by 
resistant Gram-positive bacteria including MRSA
1, peni-
cillin-resistant streptococci and vancomycin-resistant en-
terococci
2. Other causes include viral infections e.g. en-
terovirus, parvovirus B19, adenovirus, cytomegalovirus, 
Epstein-Barr virus and hepatitis B virus, as well as hyper-
sensitivity reactions to mercury
3,4. The median duration of 
treatment before onset of the rash is 1∼3 weeks. 
Histological findings include spongiform sub-corneal 
pustules with perivascular infiltrates of neutrophils and 
some eosinophils. The diagnosis of AGEP is made based 
on a clinical-pathological correlation, as there are no other 
definitive diagnostic markers. Response to discontinuation 
of medication supports the diagnosis. Differential diag-
noses include pustular psoriasis, anticonvulsive hyper-
sensitivity syndrome, subcorneal pustular dermatosis and 
superficial fungal infections, Sweet’s syndrome, toxic epi-
dermal necrolysis and erythema multiforme, particularly if 
target lesions, skin sloughing or involvement of mucous 
membranes are present
5.
AGEP resolves upon discontinuation of the implicated 
medication, which may be the only required therapeutic 
measure. Some patients may require topical corticos-
teroids to help alleviate symptoms.
Our patient had clinical and histological  findings consi-
stent with AGEP. In view of the timing of onset and resol-
ution of the rash with regards to the course of daptomycin, 
and after exclusion of other causative drugs, our patient 
most likely had AGEP secondary to daptomycin. To the 
best of our knowledge, this is the first report of AGEP 
caused by daptomycin.
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